EXOZ · Exozymes Inc. · Insider Trading

The option vests over a three (3) year period in twelve (12) equal quarterly installments of 3,750 shares at the end of each quarter of the calendar year, commencing with the first full calendar quarter following the date of grant. The first installment vests on 12/31/2026 and the final installment vests on 09/30/2029. The option expires on 09/14/2033.

The RSU convert on a one-for-one basis.

On March 28, 2022, and May 1, 2023, the reporting person was granted an aggregate of 79,104 RSUs, vesting periodically. The first vesting was August 19, 2026, in the amount of 32,964 shares of common stock.

The RSU convert on a one-for-one basis.

The RSU convert on a one-for-one basis.

The RSU convert on a one-for-one basis.

On January 14, 2026, the reporting person was granted an aggregate of 62,759 RSUs, vesting periodically. The first vesting was August 19, 2026, in the amount of 19,612 shares of common stock.

The shares underlying the stock option grant vest at a rate of 3,050 shares per month, with 36,609 shares vesting immediately. The final vesting installment consists of 3,078 shares on April 1, 2029. The grant and each exercise of the option is pursuant to Rule 16b-3 of Section 16 of the Securities and Exchange Act of 1934, as amended.

The shares underlying the grant of the restricted stock vest at a rate of 3,923 shares per quarter, with 15,689 shares vesting immediately. The final vesting installment consists of 3,917 shares on April 1, 2029. The grant and each vesting is pursuant to Rule 16b-3 of Section 16 of the Securities and Exchange Act of 1934, as amended.

The Options will vest over a four (4) year period, in equal quarterly installments at the end of each quarter of the calendar year, and the Options will commence vesting on July 1, 2025.The option expires June 29, 2032.

The reported price in Column 4 is a weighted average purchase price. The shares acquired on January 17, 2025 were purchased in multiple transactions at prices ranging from $10.45 to $11.00 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.